UK Markets close in 6 hrs 1 min

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.17-0.53 (-9.30%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 380.67
52-week low 33.59
50-day moving average 38.33
200-day moving average 312.52

Share statistics

Avg vol (3-month) 3640.39k
Avg vol (10-day) 3616.41k
Shares outstanding 542.68M
Implied shares outstanding 6N/A
Float 831.98M
% held by insiders 144.99%
% held by institutions 18.60%
Shares short (12 Aug 2021) 41.38M
Short ratio (12 Aug 2021) 41.08
Short % of float (12 Aug 2021) 43.85%
Short % of shares outstanding (12 Aug 2021) 42.67%
Shares short (prior month 14 Jul 2021) 41.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 325 Mar 2021

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -7.74M
Net income avi to common (ttm)-7.88M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)50.16M
Total cash per share (mrq)0.97
Total debt (mrq)3.63M
Total debt/equity (mrq)10.33
Current ratio (mrq)1.51
Book value per share (mrq)-0.11

Cash flow statement

Operating cash flow (ttm)-8.06M
Levered free cash flow (ttm)N/A